Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Equity Average (2019 - 2025)

BioNexus Gene Lab's Equity Average history spans 7 years, with the latest figure at $7.2 million for Q3 2025.

  • For Q3 2025, Equity Average fell 24.27% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, down 24.27%, while the annual FY2024 figure was $9.0 million, 10.16% up from the prior year.
  • Equity Average for Q3 2025 was $7.2 million at BioNexus Gene Lab, down from $7.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $9.5 million in Q1 2024 and bottomed at $5.9 million in Q2 2023.
  • The 5-year median for Equity Average is $7.2 million (2022), against an average of $7.6 million.
  • The largest annual shift saw Equity Average soared 83.94% in 2021 before it decreased 24.27% in 2025.
  • A 5-year view of Equity Average shows it stood at $7.1 million in 2021, then decreased by 8.03% to $6.5 million in 2022, then soared by 44.96% to $9.5 million in 2023, then fell by 6.66% to $8.9 million in 2024, then decreased by 19.04% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Equity Average are $7.2 million (Q3 2025), $7.6 million (Q2 2025), and $8.0 million (Q1 2025).